KTTA
Pasithea Therapeutics Corp.
$0.7060
-2.22%
$24.1M
No data for this timeframe.
Vol
Market Cap$24.1M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders3 funds
Inst. Value$189.0K
Inst. Activity2 buys / 1 sells
Recent Activity
May 13, 2026
earnings_calendar
KTTA Q1 2026 Earnings Scheduled — 2026-05-13
May 1, 2026
Insider
Novak Alfred J sold 152,783 shares
Director @ $0.00 ($0.00)
May 1, 2026
Insider
Leahy Emer sold 152,783 shares
Director @ $0.00 ($0.00)
May 1, 2026
Insider
Dumesnil Simon sold 152,783 shares
Director @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — ADD
97,675 shares ($126.0K)
Inst.
TWO SIGMA INVESTMENTS, LP — ADD
48,773 shares ($62.9K)
Price Targets
$3.00
+324.9% upside
Strong Buy
Current $0.7060
Low $3.00
Median $3.00
High $3.00
1 analysts
$3.00
$3.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 20, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Dec 8, 2025 | HC Wainwright & Co. | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.45 | $-0.45 — $-0.45 | 1 | |
| Next Q | $-0.48 | $-0.48 — $-0.48 | 1 | |
| Current FY | $-1.86 ▼ -173.5% | $-1.86 — $-1.86 | 36% YoY | 1 |
| Next FY | $-2.10 ▼ -156.1% | $-2.10 — $-2.10 | -13% YoY | 1 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $126.0K | ADD |
| TWO SIGMA INVESTMENTS, LP | $62.9K | ADD |
| BANK OF AMERICA CORP | $81.00 | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | Novak Alfred | A | $0.00 |
| May 1, 2026 | Leahy Emer | A | $0.00 |
| May 1, 2026 | Dumesnil Simon | A | $0.00 |
| May 1, 2026 | Krishnan Kartik | A | $0.00 |
| May 1, 2026 | Schneiderman Daniel | A | $0.00 |
3 institutional holders with $189.0K total value (146,511 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, BANK. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 97,675 | $126.0K | 66.7% | ADD +81.5% |
| 2 | TWO SIGMA INVESTMENTS, LP | 48,773 | $62.9K | 33.3% | ADD +36.4% |
| 3 | BANK OF AMERICA CORP /DE/ | 63 | $81.00 | 0.0% | DOUBLED +675.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 53,815 | 97,675 | +81.5% | $126.0K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 35,760 | 48,773 | +36.4% | $62.9K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 30,700 | 0 | -100.0% | $0.00 | 2025-Q4 |
| VANGUARD GROUP INC | NEW | — | 53,815 | — | $38.7K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 35,760 | — | $26.2K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 30,700 | — | $22.5K | 2025-Q3 |
| UBS Group AG | TRIM | 42,142 | 18,381 | -56.4% | $13.5K | 2025-Q3 |
| UBS Group AG | DOUBLED | 4,337 | 42,142 | +871.7% | $30.4K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 8 | 62 | +675.0% | $44.00 | 2025-Q2 |
| UBS Group AG | TRIM | 12,868 | 4,337 | -66.3% | $5.6K | 2025-Q1 |
| UBS Group AG | ADD | 6,567 | 12,868 | +95.9% | $40.5K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 1,500 | 1,000 | -33.3% | $3.1K | 2024-Q4 |
7 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | Novak Alfred J | Director | A | 152,783 | $0.00 | $0.00 |
| May 1, 2026 | Leahy Emer | Director | A | 152,783 | $0.00 | $0.00 |
| May 1, 2026 | Dumesnil Simon | Director | A | 152,783 | $0.00 | $0.00 |
| May 1, 2026 | Krishnan Kartik | Chief Medical Officer | A | 1,129,323 | $0.00 | $0.00 |
| May 1, 2026 | Schneiderman Daniel H | Chief Financial Officer | A | 1,129,323 | $0.00 | $0.00 |
| May 1, 2026 | STEINMAN LAWRENCE | Director | A | 152,783 | $0.00 | $0.00 |
| May 1, 2026 | Marques Tiago | Chief Executive Officer | A | 1,756,069 | $0.00 | $0.00 |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (86% buy). Based on 7 analysts: 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$3.00 mean target
+324.9% upside
Strong Buy (3.00)
$3.00 Low
$3.00 High
| Metric | Value |
|---|---|
| Current Price | $0.7060 |
| Target Low | $3.00 |
| Target Mean | $3.00 |
| Target Median | $3.00 |
| Target High | $3.00 |
| # Analysts | 1 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.45 | $-0.45 | $-0.45 | — | — | — | $0.0B | — | 1 |
| Next Q 2026-09-30 |
$-0.48 | $-0.48 | $-0.48 | — | — | — | $0.0B | — | 1 |
| Current FY 2026-12-31 |
$-1.86 | $-1.86 | $-1.86 | 36.1% | -173.5% | — | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-2.10 | $-2.10 | $-2.10 | -12.9% | -156.1% | — | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.450 | |
| 7d ago | $0.000 | -0.450 |
| 30d ago | $0.000 | -0.450 |
| 60d ago | $0.000 | -0.450 |
| 90d ago | $0.000 | -0.450 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 20, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 8, 2025 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 13, 2026
earnings_calendar
KTTA Q1 2026 Earnings Scheduled — 2026-05-13
May 4, 2026
other
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
Apr 20, 2026
other
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
Apr 10, 2026
short_interest
FTD: KTTA — 2,177,235 shares ($1.6M) failed to deliver
Settlement: 20260410, Price: $0.72, FTD Value: $1,567,609.2, PASITHEA THERAPEUTICS CORP COM
Apr 1, 2026
other
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of NF1 Associated Plexiform Neurofibromas
Mar 23, 2026
earnings_calendar
KTTA Q4 2025 Earnings Scheduled — 2026-03-23